Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GED 0507-34-Levo

Next Previous
Search
Drug Profile

GED 0507-34-Levo

Alternative Names: GED-0507; GED-0507-34; N-acetyl-GED-0507-34; NAC-GED-0507

Latest Information Update: 23 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Giuliani S.p.A
  • Developer Giuliani S.p.A; PPM services
  • Class Anti-inflammatories; Antiulcers
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris
  • No development reported Idiopathic pulmonary fibrosis; Ulcerative colitis

Most Recent Events

  • 16 Sep 2024 PPM Services plans a phase III trial in Acne vulgaris in England, France, Italy, Poland, Spain, United Kingdom(Topical) (ISRCTN18067422)
  • 26 Jan 2023 GED 0507-34-Levo licensed to Torii Pharmaceutical for the treatment of Acne vulgaris in Japan
  • 26 Jan 2023 Efficacy and adverse events data from a phase IIb trial in Acne vulgaris released by Nogra Pharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top